Abstract
Progranulin is a cysteine-rich secreted protein with diverse pleiotropic actions and participates in several processes, such as inflammation or tumorigenesis. Progranulin was first identified as a growth factor and, recently, it was characterised as an adipokine implicated in obesity, insulin resistance and rheumatic disease. At a central level, progranulin acts as a neurotropic and neuroprotective factor and protects from neural degeneration. In this review, we summarise the most recent research advances concerning the potential role of progranulin as a therapeutic target and biomarker in cancer, neurodegenerative and inflammatory diseases.
Cite
CITATION STYLE
Abella, V., Pino, J., Scotece, M., Conde, J., Lago, F., Gonzalez-Gay, M. A., … Gualillo, O. (2017, October 1). Progranulin as a biomarker and potential therapeutic agent. Drug Discovery Today. Elsevier Ltd. https://doi.org/10.1016/j.drudis.2017.06.006
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.